Cutler Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

Cutler Group’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,000	Closed	-$7K	–	5975
2022 Q1	$7K	Buy	+9,000	New	+$57.2K	﹤0.01%	3948

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cutler Group's RUBY Position: Q2 2022 in Review

Cutler Group sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 7,015 shares — an estimated $11.8K sold.

Cutler Group first reported a position in RUBY in Q1 2022 and held it in 1 quarter. The position peaked at $38K in Q1 2022. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

Cutler Group reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
Cutler Group sold 7,015 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $11.8K.
Cutler Group first reported a position in Rubius Therapeutics, Inc in Q1 2022 and held it in 1 quarter.
Cutler Group's Rubius Therapeutics, Inc position peaked at $38K in Q1 2022.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.